Bexarotene combined with lapatinib for the treatment of Cushing’s disease:evidence based on drug repositioning and experimental confirmation
作者机构：Institute of Materia MedicaChinese Academy of Medical Science and Peking Union Medical College1 Xian Nong Tan Street100050 BeijingChina Beijing Key Laboratory of Drug Targets Identification and Drug Screening100050 BeijingChina The State Key Laboratory of Bioactive Substance and Function of Natural Medicines1 Xian Nong Tan Street100050 BeijingChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2020年第5卷第1期
页 面：988-990页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学]
基 金：supported by National Natural Science Foundation of China(Grant No:81670456) Drug Innovation Major Project of China(No.2018ZX09711001-003-001) Natural Science Foundation of Beijing Municipality(CN)(Grant No:7162132) CAMS Innovation Fund for Medical Sciences(Grant No:2017-I2M-1-011)
摘 要：Dear Editor,Cushing’s disease(CD)is a rare disease manifested as Cushing’s syndrome caused by adrenocorticotropic hormone(ACTH)consistently over-secreted by adrenocorticotropic adenomas,followed by stimulation of the adrenal gland to secrete considerable cortisol,triggering metabolic dysfunction,and leading to death from ***,pituitary adrenocorticotropic adenoma-directed drugs can only inhibit ACTH secretion or hamper tumour growth,which limits their clinical ***,Nur77(also known as NR4A1 and NGFI-Ba,a kind of nuclear receptor),an important positive transcription regulator of pro-opiomelanocortin(POMC),the precursor of ACTH,has been regarded as a promising CD target.1 Hence,it would be promising to identify a combination treatment that targets Nur77 and another CD target to cover hormone normalisation in the short term and tumour suppression or even elimination in the long term.
维普期刊数据库